You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 4
  • EP772 Testing for concordance of somatic and germline BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy: large single-site institution experience

Citation Tools

Article menu
Download PDFPDF
ePoster
EP772 Testing for concordance of somatic and germline BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy: large single-site institution experience

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Akaev I, Chau C, Uherek M, et al
EP772 Testing for concordance of somatic and germline BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy: large single-site institution experience
International Journal of Gynecologic Cancer 2019;29:A429.